Combination treatment of KBM5 and KBM5-STI571 cells with Sur-AS-OND and imatinib. KBM5 and KBM5-STI571 cells were treated with Sur-AS-ODN for 24 hours. Imatinib was added for an additional 48 hours. (A) Cell death was analyzed by annexin V positivity. (B) Survivin protein levels were determined by Western blot analysis. Sol cont indicates solution T control; prog cont, nucleofection program K17 control; NS, Sur-NS-ODN control; AS, Sur-AS-ODN.